全文获取类型
收费全文 | 15028篇 |
免费 | 1176篇 |
国内免费 | 551篇 |
专业分类
耳鼻咽喉 | 66篇 |
儿科学 | 169篇 |
妇产科学 | 149篇 |
基础医学 | 784篇 |
口腔科学 | 593篇 |
临床医学 | 1454篇 |
内科学 | 2644篇 |
皮肤病学 | 392篇 |
神经病学 | 504篇 |
特种医学 | 643篇 |
外科学 | 1524篇 |
综合类 | 1534篇 |
现状与发展 | 1篇 |
预防医学 | 772篇 |
眼科学 | 148篇 |
药学 | 3978篇 |
4篇 | |
中国医学 | 180篇 |
肿瘤学 | 1216篇 |
出版年
2023年 | 183篇 |
2022年 | 264篇 |
2021年 | 513篇 |
2020年 | 518篇 |
2019年 | 544篇 |
2018年 | 548篇 |
2017年 | 528篇 |
2016年 | 587篇 |
2015年 | 622篇 |
2014年 | 867篇 |
2013年 | 1561篇 |
2012年 | 872篇 |
2011年 | 928篇 |
2010年 | 721篇 |
2009年 | 689篇 |
2008年 | 699篇 |
2007年 | 709篇 |
2006年 | 574篇 |
2005年 | 598篇 |
2004年 | 481篇 |
2003年 | 454篇 |
2002年 | 380篇 |
2001年 | 310篇 |
2000年 | 260篇 |
1999年 | 198篇 |
1998年 | 162篇 |
1997年 | 200篇 |
1996年 | 124篇 |
1995年 | 151篇 |
1994年 | 127篇 |
1993年 | 133篇 |
1992年 | 115篇 |
1991年 | 114篇 |
1990年 | 92篇 |
1989年 | 91篇 |
1988年 | 90篇 |
1987年 | 94篇 |
1986年 | 73篇 |
1985年 | 80篇 |
1984年 | 79篇 |
1983年 | 60篇 |
1982年 | 57篇 |
1981年 | 45篇 |
1980年 | 44篇 |
1979年 | 41篇 |
1978年 | 38篇 |
1977年 | 28篇 |
1976年 | 32篇 |
1974年 | 16篇 |
1973年 | 16篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
51.
52.
53.
R. Ferrara S. Pilotto U. Peretti M. Caccese S. Kinspergher L. Carbognin 《Expert opinion on pharmacotherapy》2016,17(8):1113-1129
Introduction: Although the advent of target therapy for lung cancer has brought about outstanding results, this benefit is confined to a subgroup of molecularly selected patients, whereas for most non-small cell lung cancer (NSCLC) patients, chemotherapy still represents the milestone of treatment. Since their introduction into clinics, microtubule targeting agents (MTA), including vinca alkaloids and taxanes, have been extensively used for NSCLC in different settings and combinations.Areas Covered: In this review, MTA are classified according to their mechanism of action, with a focus on the most common mechanisms of resistance. Moreover, an overview of the most remarkable clinical data regarding MTA in adjuvant, neoadjuvant and advanced setting is provided. Finally, the novel mitotic kinases inhibitors are described according to their different mechanism of action and clinical activity compared to MTA.Expert Opinion: Unfortunately, the awaited benefit deriving from the actually available chemotherapeutic regimens for advanced NSCLC has reached a plateau. In this scenario, the identification of reliable predictive biomarkers represents a major challenge. Moreover, different schedules for MTA administration are currently under investigation, such as the combination of MTA with other drugs able to bypass the resistance derived from the ‘mitotic slippage’ and the use of metronomic administration of spindle poisons with anti-angiogenic or immunomodulatory agents. 相似文献
54.
55.
《Gaceta sanitaria / S.E.S.P.A.S》2015,29(4):304-307
Anabolic androgenic steroids (AAS) can cause serious adverse effects when used without a therapeutic purpose. This article aims to show that the AAS are susceptible to being sold on the black market. We also aim to describe how certain limitations on the health inspection services of the Galician health service to pursue these illegal actions prompted a regulatory initiative demanding that additional actions be granted to community pharmacies when dispensing AAS. Four pharmacy inspections detected the diversion of a total of 3118 packages of AAS, which led to the opening of four disciplinary proceedings. In two of these, specialized police forces were called in as there was sufficient evidence of possible diversion to gymnasiums, resulting in a police operation called Operation Fitness. 相似文献
56.
2015年中华医学会感染病学分会艾滋病学组发布了第三版《艾滋病诊疗指南》。新版指南强调抗病毒治疗时点前移:一旦成人确诊感染人类免疫缺陷病毒(HIV), 若无禁忌宜尽早启动抗HIV治疗。对于合并机会性感染的HIV感染者, 在感染控制、病情稳定后也应及早开始抗病毒治疗。尤其强调HIV合并结核患者在CD4阳性淋巴细胞数少于200/μL的情况下, 建议抗结核两周内即开始抗病毒治疗。在抗HIV治疗用药中, 淘汰了一些毒副作用大、依从性较差的药物, 如司他夫定、去羟肌苷、茚地那韦等, 优选抗病毒效力强、服药方便的组合, 如拉米夫定、替诺福韦、依非韦伦组合。对于HIV感染的婴幼儿, 亦主张及早抗HIV治疗。对于五岁以内的幼儿, 主张确诊后即启动抗病毒治疗。对于HIV感染的孕产妇, 建议尽快予以全程、联合抗HIV治疗, 寓防于治。 相似文献
57.
Joshua Manghelli Lisa Brown Hany B. Tadros Nabil A. Munfakh 《Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital》2015,42(5):491-494
The inflammatory response induced by cardiopulmonary bypass decreases vascular tone, which in turn can lead to vasoplegic syndrome. Indeed the hypotension consequent to on-pump cardiac surgery often necessitates vasopressor and intravenous fluid support. Methylene blue counteracts vasoplegic syndrome by inhibiting the formation of nitric oxide.We report the use of methylene blue in a 75-year-old man who developed vasoplegic syndrome after cardiac surgery. After the administration of methylene blue, his hypotension improved to the extent that he could be weaned from vasopressors. The use of methylene blue should be considered in patients who develop hypotension refractory to standard treatment after cardiac surgery. 相似文献
58.
Rohi Shah Nomaan Sheikh Jitendra Mangwani Nicolette Morgan Hamidreza Khairandish 《Journal of Clinical Orthopaedics and Trauma》2021,12(1):138
Demographic projections for hip fragility fractures indicate a rising annual incidence by virtue of a multimorbid, ageing population with more noncommunicable diseases (NCDs). NCDs are characterised by slow progression and long duration ranging from ischaemic cardiovascular disease, cerebrovascular disease, diabetes, chronic obstructive pulmonary disease to various cancers. Management of this disease burden often involves commencing patients on oral anticoagulants to reduce the risk of thromboembolic events. The use of direct oral anticoagulants (DOACs) in clinical practice has increased due to their rapid onset of action, short half-life and predictable anticoagulant effects, without the need for routine monitoring. Safe and timely surgical intervention relies on reversal of anticoagulants. However, the lack of specific evidence-based guidelines for the perioperative management of patients on DOACs with hip fractures has proved challenging; in particular, the accessibility of DOAC-specific assays, justification of the cost-benefit ratio of targeted reversal agents and indications for neuraxial anaesthesia. This has led to potentially avoidable delays in surgical intervention. Following a literature review of the pharmacokinetic and pharmacodynamics of commonly used DOACs in our region including the role of surrogate markers, we propose a systematic, evidence-based guideline to the perioperative management of hip fractures DOACs. We believe this standardised protocol can be easily replicated between hospitals. We recommend that if patients are deemed suitable for a general anaesthesia, with satisfactory renal function, optimal surgical time should be 24 h following the last ingested dose of DOAC. 相似文献
59.
《Journal of microbiology, immunology, and infection》2021,54(5):767-775
Despite aggressive efforts on containment measures for the coronavirus disease 2019 (COVID-19) pandemic around the world, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuously spreading. Therefore, there is an urgent need for an effective antiviral agent. To date, considerable research has been conducted to develop different approaches to COVID-19 therapy. In addition to early observational studies, which could be limited by study design, small sample size, non-randomized design, or different timings of treatment, an increasing number of randomized controlled trials (RCTs) investigating the clinical efficacy and safety of antiviral agents are being carried out. This study reviews the updated findings of RCTs regarding the clinical efficacy of eight antiviral agents against COVID-19, including remdesivir, lopinavir/ritonavir, favipiravir, sofosbuvir/daclatasvir, sofosbuvir/ledipasvir, baloxavir, umifenovir, darunavir/cobicistat, and their combinations. Treatment with remdesivir could accelerate clinical improvement; however, it lacked additional survival benefits. Moreover, 5-day regimen of remdesivir might show adequate effectiveness in patients with mild to moderate COVID-19. Favipiravir was only marginally effective regarding clinical improvement and virological assessment based on the results of small RCTs. The present evidence suggests that sofosbuvir/daclatasvir may improve survival and clinical outcomes in patients with COVID-19. However, the sample sizes for analysis were relatively small, and all studies were exclusively conducted in Iran. Further larger RCTs in other countries are warranted to support these findings. In contrast, the present findings of limited RCTs did not indicate the use of lopinavir/ritonavir, sofosbuvir/ledipasvir, baloxavir, umifenovir, and darunavir/cobicistat in the treatment of patients hospitalized for COVID-19. 相似文献
60.
目的 分析我院147例泌尿系感染住院患儿的临床及治疗情况,并结合国内外新的研究进展,为临床诊治提供参考依据。方法 应用描述性方法对我院2016年5月至2020年5月住院的147例泌尿系感染病例进行回顾性分析。结果 147例患儿中,男性88例(59.86%)。婴儿期人数最多,共63例(42.86%)。尿培养中以屎肠球菌及大肠埃希菌多见。治疗上有136例(92.52%)选用头孢菌素类抗生素,其中三代头孢有132例(89.80%);45例行排泄性膀胱输尿管造影的患儿中有22例(48.89%)存在膀胱输尿管返流。结论 泌尿系感染是儿童的常见病,由于它与泌尿系畸形特别是膀胱输尿管返流密切相关,易导致感染反复,因此早期诊治并寻找其潜在的畸形,可预防复发,改善预后。 相似文献